Skip to Main content Skip to Navigation
Journal articles

Innovation in Bladder Cancer Immunotherapy

Abstract : Bladder cancer is understudied despite its high prevalence and its remarkable response to immunotherapy. Indeed, funding for studies to explore mechanisms of tumor immunity and novel new therapeutics is disproportionately lower for bladder cancer in comparison with malignancies of the breast, prostate, or lung. However, the recent successes of checkpoint blockade therapy suggest that new therapeutic strategies are on the horizon for bladder cancer. Here, we give a perspective into the evolution of bladder cancer therapy, focusing on strategies to treat high-risk nonmuscle invasive disease, followed by a discussion of recent advances in the treatment of muscle invasive bladder cancer and their potential applicability to lower stage disease. Finally, we explore immunotherapeutic strategies, which have been demonstrated to be successful in the treatment of other malignancies, for their potential to treat and cure patients with nonmuscle and muscle invasive bladder cancer.
Document type :
Journal articles
Complete list of metadatas

https://hal-pasteur.archives-ouvertes.fr/pasteur-01380581
Contributor : Marie-Christine Vougny <>
Submitted on : Thursday, October 13, 2016 - 10:57:37 AM
Last modification on : Thursday, April 2, 2020 - 3:18:01 PM

Identifiers

Collections

Citation

H. Barton Grossman, Donald L. Lamm, Ashish M. Kamat, Stephen Keefe, John A. Taylor, et al.. Innovation in Bladder Cancer Immunotherapy. Journal of Immunotherapy, Lippincott, Williams & Wilkins, 2016, 39 (8), pp.291 - 297. ⟨10.1097/CJI.0000000000000130⟩. ⟨pasteur-01380581⟩

Share

Metrics

Record views

189